Control
Losmapimod is an oral, small molecule anti-inflammatory drug that selectively inhibits the p38 mitogen-activated protein kinase (MAPK) pathway.
Mar 31 2021 |
et al., NCT04511819 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Losmapimod in Adult Subjects With COVID-19 (LOSVID STUDY) |
| 18% higher progression (p=0.54) and 14% worse recovery (p=0.64). RCT 52 hospitalized COVID-19 patients showing no significant differences with losmapimod treatment. | ||
Please send us corrections, updates, or comments.
c19early involves the extraction of 200,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. IMA and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.